{'fraction_non_alphanumeric': 0.03008849557522124, 'fraction_numerical': 0.047787610619469026, 'mean_word_length': 4.66, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long-term results of intratumorous bleomycin-A5 injection for head and neck lymphangioma.

From June 1987 to June 1995, 200 patients with various types of head and neck lymphangioma were treated by intratumorous injection of bleomycin-A5. All 200 cases were followed from 2 to 10 years; 95 cases were followed for more than 5 years. The effective rate was 97%, and the curative rate was 86.5%. No pulmofibrosis or other serious complications were found. The relationships between the curative effect and tumor type, size, and side effect of bleomycin are discussed.